Special AT-rich sequence-binding protein 2(SATB2) is a peculiar marker in the diagnosis of colorectal carcinoma (CRC), SATB2 has been employed as a colorectal differentiation marker with the potential to be useful in distinguishing the origin of adenocarcinomas of unknown primary origin. Also SATB2 inhibit colorectal cancer progression and low expression of SATB2 protein has been associated with low survival outcome. The aim of the study was to assess the SATB2 immunohistochemical expression in CRC, and association with several clinicopathological characteristics. Immunohistochemical staining for SATB2 was done on 70 cases of colorectal adenocarcinoma that underwent colectomy. Their expressions were analysed as negative, intermediate and strong then correlated to clinico-pathological parameters in an attempt to obtain the most significant predictors of SATB2. SATB2 score was negative in 30 %of the cases, intermediate in 54.3% and strong in 15.7%. Strong SATB2 expression was significantly associated with a low tumor histological grade (P = 0.007), a low tumor invasiveness stage (P = 0.001), the absence of lymph node metastasis (P = 0.001), the absence of detected distant metastasis (P = 0.039), a low TNM stage (P = 0.001), a low modified Dukes stage (P = 0.001), the absence of lympho-vascular invasion (P value 0.001) and the absence of perineural invasion (P = 0.001).A High rate of SATB2 expression was associated with left colon tumors and adenocarcinoma histological type, but without a statistically significant correlation. In the cases analyzed, there was no significant association between SATB2 expression and age, sex, or tumor size. Strong SATB2 expression is associated with the accepted clinicopathological parameters favoring good prognosis in the colorectal cancer and may represent a potential therapeutic target.